Evidence map›Paper›PMID 41874424›Full record

ArticleJournal of the Pediatric Infectious Diseases Society2026

Safety and Pharmacokinetics of Nirsevimab in Japanese Infants: Primary Analysis of the Open-Label JUBILUS Trial.

Masaaki Mori, Susannah Leach, Maria Learoyd, Divya Vijapur, Sam Sadow, Deidre Wilkins, Yoshifusa Abe, Kazushige Ikeda, Hirokazu Kanegane, Zempei Kano and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Pediatric Infectious Diseases Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Masaaki MoriDepartment of Lifelong Immunotherapy, Institute of Science Tokyo, Tokyo, Japan.ORCID 0000-0003-2130-4866
Susannah LeachVaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.
Maria LearoydClinical Pharmacology & Safety Sciences, AstraZeneca, Cambridge, United Kingdom.
Divya VijapurGlobal Patient Safety Biopharma, Chief Medical Office, R&D, AstraZeneca, Luton, United Kingdom.
Sam SadowLate Vaccine and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.
Deidre WilkinsTranslational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.
Yoshifusa AbeChildren's Medical Center, Showa Medical University Koto Toyosu Hospital, Tokyo, Japan.
Kazushige IkedaDivision of Neonatology, Department of Pediatrics, Saitama City Hospital, Saitama, Japan.ORCID 0000-0002-3097-2156
Hirokazu KaneganeDepartment of Child Health and Development, Graduate School of Medicine and Dental Sciences, Institute of Science Tokyo Hospital, Tokyo, Japan.ORCID 0000-0002-8696-9378
Zempei KanoDepartment of General Pediatrics and Interdisciplinary Medicine, Fukuoka Children's Hospital, Fukuoka, Japan.
Hiroyuki MoriuchiNational Research Centre for the Control and Prevention of Infectious Diseases, Nagasaki University Hosptial, Nagasaki, Japan.
Jun MuneuchiDepartment of Pediatrics, Kyushu Hospital, Japan Community Healthcare Organization, Fukuoka, Japan.
Ryuta NishikomoriDepartment of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Japan.ORCID 0000-0002-9407-6158
Kaoru OkazakiDepartment of Neonatology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Therese TakasVaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.
Ayako SakaguchiBiopharmaceuticals R&D Japan, AstraZeneca K.K., Tokyo, Japan.
Tonya VillafanaVaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.

Funding

AstraZeneca
6 · The paper itself

Abstract

In Japanese infants aged ≤12 months at risk for severe respiratory syncytial virus-associated lower respiratory tract infections who received two doses of nirsevimab 5-6 months apart, no safety concerns or anti-drug antibodies occurred. Nirsevimab serum concentrations were consistent with those previously demonstrated to be efficacious in healthy preterm and term infants.

Indexed as

Antibodies, Monoclonal, HumanizedAntiviral AgentsRespiratory Syncytial Virus InfectionsRespiratory Tract InfectionsEast Asian PeopleFemaleHumansInfantInfant, NewbornJapanMaleAntibodies, Monoclonal, HumanizedAntiviral Agentsinfantmonoclonal antibodynirsevimabrespiratory syncytial virus infectionsrespiratory tract infection

Identifiers

PMID41874424
PMCPMC13025070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.